BLUE ISLAND, IL - January 30, 2025 (NEWMEDIAWIRE) - Shear Kershman Laboratories, a leader in healthcare innovation, Texas A&M University College of Dentistry, a globally recognized institution in oral healthcare and education, and Innovative MedTech Inc. (OTC: IMTH), a cutting-edge medical technology developer, have signed a Memorandum of Understanding (MOU) to collaborate on transformative healthcare initiatives in oral care.
Commenting on the MOU, Michael Friedman, President & CEO of Innovative MedTech, stated, “The MOU sets the foundation for a strategic partnership aimed at advancing medical and dental technologies, enhancing patient care, and fostering groundbreaking research. By combining Shear Kershman Labs’ healthcare expertise, Texas A&M’s academic and research excellence, and Innovative MedTech’s technological prowess, the collaboration is poised to redefine the future of healthcare delivery and innovation. We are incredibly excited to be leading the charge in developing what we view as a revolutionary therapeutic platform for oral care.”
A Shared Vision for Innovation and Impact
Under the terms of the MOU, the three organizations will:
- Develop Innovative Solutions: Jointly design and implement advanced technologies to address critical challenges in oral health and overall patient care.
- Advance Education and Training: Enhance academic programs and provide practical training opportunities for students and professionals to ensure the next generation of healthcare providers is equipped with cutting-edge knowledge and skills.
- Promote Collaborative Research: Conduct groundbreaking studies and clinical trials to drive medical and dental advancements, with a focus on improving patient outcomes globally.
Focus on Bioequivalency Study for Oral Thrush Treatment
A key component of the MOU includes a bioequivalency study for Oral Thrush, also known as oral candidiasis. Shear Kershman Labs has developed a long-lasting formulation, BioViscid™, which is designed to provide highly effective bio-adhesion across both dry and mucosal tissues. Early trials with volunteers affected by thrush indicate that BioViscid™ delivers sustained release profiles over 6-8 hours post-application. Initial data from in vitro tests demonstrate that BioViscid™ maintains its adherence and controlled release properties even in high-moisture environments (including eating and drinking), while showing no adverse reactions on skin or mucosal tissues.
With its unique combination as an amphipathic molecule and bio-adhesive encapsulation, BioViscid™ establishes itself as a pioneering technology in drug delivery. This innovation maximizes therapeutic effects and convenience for users, making it a transformative platform for medical and consumer health applications requiring stability, controlled release, and targeted application.
Unlike existing treatments like fluconazole or amphotericin B, which are often systemically administered, BioViscid™ represents a significant advancement as it adheres to the mucosal cavity and avoids first-pass metabolism, enhancing efficacy and patient experience.
Leadership Perspectives
“BioViscid™ represents a breakthrough in the treatment of oral thrush,” said Dr. Blake Hawley, of Shear Kershman Labs. “Unlike current options, our formulation ensures sustained contact with the affected area, dramatically improving therapeutic outcomes and patient convenience.”
Dr. Lily T. Garcia, Dean of Texas A&M College of Dentistry, stated, “This partnership exemplifies the transformative potential of collaboration between academia and industry. BioViscid™ represents more than innovation; it is a testament to the remarkable outcomes possible when science, technology, and patient care align. We are excited to see the impact this will have on advancing oral healthcare.”
Oral Thrush: Prevalence and Market Opportunity
Oral candidiasis, commonly known as oral thrush, affects approximately 5-7% of Americans, particularly those with weakened immune systems, infants, elderly individuals, and people using certain medications (like corticosteroids or antibiotics) that disrupt normal microbial balance. Populations at higher risk include those with diabetes, HIV/AIDS, or cancer, as well as individuals using dentures. This prevalence translates to millions of cases annually in the U.S.
The global market size for oral candidiasis treatments is estimated to be around $4-6 billion, driven by prescription and over-the-counter antifungal medications, mouth rinses, and topical formulations. This market is expected to grow with the aging population, increasing incidence of immunocompromised conditions, and a rising awareness of the need for effective treatment options. Novel drug delivery systems, such as bio-adhesive or sustained-release formulations, are positioned to revolutionize this space.
Anticipated Impact
The collaboration is expected to produce significant breakthroughs, including:
- The development of novel drug delivery methods for oral diseases.
- Innovative treatment solutions to improve patient care in underserved communities.
- Enhanced curriculum offerings at Texas A&M College of Dentistry to bridge the gap between technology and traditional practice.
About Shear Kershman Labs
Shear Kershman Labs is a healthcare innovation company dedicated to delivering cutting-edge solutions that transform patient care and streamline healthcare delivery systems. For more information, visit https://shearkershmanlabs.com
About Texas A&M University College of Dentistry
Texas A&M College of Dentistry is a premier institution committed to advancing oral health through education, research, and specialized patient care. Learn more at https://dentistry.tamu.edu.
About Innovative MedTech Inc.
Innovative MedTech Inc. (OTC: IMTH or the “Company”) is a pioneer in medical technology, specializing in the development of advanced tools and systems to revolutionize healthcare. IMTH is the exclusive licensor for the Oral Thrush application of Shear Kershman Labs’ BioViscid™ bio-adhesive encapsulation. IMTH is also a provider of medical technology and devices as well as health and wellness services through its wholly owned subsidiary SarahCare, an adult day care center franchisor with two corporate owned centers and twenty-five franchise locations across the U.S. SarahCare offers seniors daytime care and activities ranging from exercise and medical needs daily to nursing care and salon services. For more information, visit https://www.innovativemedtech.com.
Safe Harbor Statement
Statements in this press release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and are not guarantees of future performance and are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations and are subject to change at any time. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify, develop and achieve commercial success; the level of expenditures necessary to develop, maintain and improve the quality of products or services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. These and other important factors may cause the Company’s actual results, performance, or achievements to differ materially from any future results, performance, achievements or plans expressed or implied by these forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
IMTH Contact: Media Relations:
Michael Friedman
708-925-9424
ir@innovativemedtechinc.com
Shear Kershman Labs Media Contact:
Dr. Blake Hawley, CEO
blake@motegahealth.com
(m) 785-260-1094
www.ShearKershmanLabs.com
View the original release on www.newmediawire.com
